What is a multiparametric prostate MRI (PRAD) and what clinical findings, such as an elevated prostate-specific antigen (PSA), would trigger ordering this test?

What is PRAD and What Triggers This Test?

"PRAD" likely refers to multiparametric prostate MRI (mpMRI), and this test should be ordered when there is clinical suspicion of prostate cancer—most commonly triggered by elevated PSA, abnormal digital rectal examination (DRE), or prior negative biopsies with persistent concern for cancer. 1, 2

Understanding Multiparametric Prostate MRI

Multiparametric MRI (mpMRI) is an advanced imaging technique that combines multiple MRI sequences to detect and localize clinically significant prostate cancer. The "multiparametric" designation refers to the combination of:

• T2-weighted imaging (anatomic detail)
• Diffusion-weighted imaging (cellular density)
• Dynamic contrast-enhanced imaging (blood flow patterns)

Results are reported using the PI-RADS (Prostate Imaging-Reporting and Data System) scoring system, which grades suspicious lesions from 1-5, with higher scores indicating greater likelihood of clinically significant cancer 1.

Clinical Triggers for Ordering mpMRI

Primary Indications:

1. Biopsy-Naïve Patients with Elevated PSA

• PSA > 4 ng/mL is the traditional threshold, though this should be interpreted with clinical context 3, 4
• PSA density (PSAD) > 0.15 ng/mL/cc is a stronger predictor and should prompt mpMRI consideration 1, 5, 6
• Abnormal DRE findings warrant mpMRI, though the test may be less predictive in this specific scenario 5

The evidence shows mpMRI before first biopsy improves detection of clinically significant cancer while reducing overdiagnosis of indolent disease. In biopsy-naïve patients, suspicious lesions (PI-RADS 4-5) are found in approximately 49% of cases, with 86% showing positive targeted biopsies 2.

2. Prior Negative Biopsy with Persistent Suspicion

• This is a particularly strong indication for mpMRI 1, 2
• After one negative TRUS biopsy, mpMRI detects intermediate- to high-value targets in 32-45% of patients 2
• Cancer detection rates with MRI-guided biopsy reach 41-89% depending on PI-RADS score 2
• Standard repeat TRUS biopsies miss anterior and apical cancers that mpMRI can identify 1

3. Active Surveillance Candidates

• Men with low-risk prostate cancer considering or already on active surveillance 1, 7
• mpMRI helps exclude higher-grade disease missed on initial biopsy (20-36% of low-risk patients have unfavorable pathology on prostatectomy) 1
• A negative mpMRI is reassuring, with only 9% of such patients reclassified to higher-risk disease 2

4. Surgical Planning for Benign Prostatic Enlargement

• Men with elevated PSA who need surgery for benign prostatic hyperplasia 8
• mpMRI can potentially avoid unnecessary biopsies in this population (NPV 95% for clinically significant cancer) 8

Optimal Strategy: Combining mpMRI with PSA Density

The most evidence-based approach is to biopsy patients with PI-RADS 4-5 lesions OR PI-RADS 3 lesions with PSAD ≥ 0.15 ng/mL/cc 1, 6. This strategy:

• Achieves 91% negative predictive value
• Avoids 16% of unnecessary biopsies
• Misses only 4% of clinically significant cancers
• Reduces overdiagnosis of insignificant cancer by 9% 6

Management Algorithm Based on PI-RADS Score:

PI-RADS 1-2 (Negative/Low Suspicion):

• No immediate biopsy if not otherwise high-risk
• Consider urologic follow-up
• If high clinical risk factors present (family history, very high PSA, high PSAD), may still consider TRUS biopsy 1

PI-RADS 3 (Equivocal):

• Use PSAD as tiebreaker
• If PSAD < 0.15: defer biopsy, monitor
• If PSAD ≥ 0.15: proceed with targeted + systematic biopsy 1, 6

PI-RADS 4-5 (High Suspicion):

• Proceed with MRI-targeted biopsy plus systematic sampling 1, 2
• Cancer detection rates: 42% for PI-RADS 4,88-89% for PI-RADS 5 2

Important Caveats:

• Image quality is critical: 99% of scans must meet adequate diagnostic quality standards 9
• Suspicious DRE may warrant biopsy regardless of mpMRI findings, as mpMRI is less predictive in this specific scenario 5
• Biparametric MRI (without contrast) is noninferior to full multiparametric MRI and may become the new standard, offering cost savings and increased scanner throughput 9
• mpMRI works best when radiologists and urologists collaborate in multidisciplinary teams 1

Key Benefits of Pre-Biopsy mpMRI:

• Detects 30-40% more clinically significant cancers compared to systematic biopsy alone
• Reduces detection of clinically insignificant cancer by approximately 50%
• Allows fewer targeted cores per patient
• Enables some patients to avoid biopsy entirely (those with negative mpMRI and low clinical risk) 1